Screener
Spyre Therapeutics, Inc. SYRE Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| CVR liability | 50,260 | 22,820 |
| Accrued and other current liabilities | 29,160 | 26,947 |
| Related party accounts payable | 50 | 14 |
| Total current liabilities | 85,162 | 58,685 |
| Non-current CVR liability | 6,690 | 3,860 |
| Other non-current liabilities | 1,290 | — |
| TOTAL LIABILITIES | 93,142 | 62,545 |
| Commitments and Contingencies (Notes 6 and 7) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s total current liabilities?
- Spyre Therapeutics, Inc. (SYRE) reported total current liabilities of $85.16M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Spyre Therapeutics, Inc.'s total current liabilities increased by 20.5% year-over-year, from $70.68M to $85.16M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s total current liabilities has grown at a 29.0% compound annual growth rate (CAGR), from $16.44M to $58.69M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Spyre Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude